Bempedoic Acid: Clinical Overview
Indications
Bempedoic acid is FDA-approved for two primary indications: reducing cardiovascular risk in adults unable to take recommended statin therapy (including those not taking statins) with established CVD or high CVD risk, and as adjunctive therapy to lower LDL-C in adults with primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH) 1.
The drug works by inhibiting ATP-citrate lyase, an enzyme upstream of HMG-CoA reductase in the cholesterol synthesis pathway 2. A critical advantage is that bempedoic acid is a prodrug activated only in the liver by very-long-chain acyl-CoA synthetase-1, an enzyme absent in skeletal muscle 2. This hepatic-specific activation explains why it does not cause the muscle-related adverse effects typical of statins, making it particularly valuable for statin-intolerant patients.
Target Patient Populations:
- Adults with ASCVD or HeFH requiring additional LDL-C lowering on maximally tolerated statin therapy 2
- Statin-intolerant patients with history of statin-associated muscle symptoms 3
- High-risk patients unable to achieve LDL-C goals with statins alone 4
Dosing
The recommended dose is 180 mg orally once daily, with or without food 2, 1. This single fixed dose simplifies administration and has been validated across multiple clinical trials.
Expected LDL-C Reductions:
- Monotherapy (in statin-intolerant patients): approximately 24.5% reduction 2
- Added to statin therapy: 17-18% additional reduction 2
- Fixed-dose combination with ezetimibe plus statin: 38% additional reduction 2
Lipid levels should be analyzed 8-12 weeks after initiation 1. The LDL-C lowering effect occurs early, with significant reductions observed by 3 months and sustained through 12 months 5.
Drug Interactions to Avoid:
- Do not use with simvastatin >20 mg daily 2
- Do not use with pravastatin >40 mg daily 2
- When using the combination product with bile acid sequestrants, administer bempedoic acid/ezetimibe either 2 hours before or 4 hours after the sequestrant 2
Monitoring Requirements
Uric Acid Monitoring:
Assess serum uric acid before initiation and periodically as clinically indicated 2, 1. Bempedoic acid inhibits renal tubular OAT2, leading to increased blood uric acid levels 1.
- In primary hyperlipidemia trials, 26% of patients developed hyperuricemia (vs 9.5% placebo) 1
- Mean placebo-adjusted increase: 0.8 mg/dL after 12 weeks 1
- In the cardiovascular outcomes trial, 16.4% experienced clinically significant hyperuricemia (vs 8.2% placebo) 1
- Gout occurred in 3.2% of patients (vs 2.2% placebo) in the outcomes trial 1
Monitor for signs and symptoms of hyperuricemia throughout treatment and initiate urate-lowering therapy as appropriate 2.
Tendon Monitoring:
Assess for tendon-related symptoms at each visit 1. Bempedoic acid carries an increased risk of tendon rupture:
- 0.5% incidence in primary trials (vs 0% placebo) 2
- 1.2% in cardiovascular outcomes trial (vs 0.9% placebo) 1
- Higher risk in patients >60 years, those taking corticosteroids or fluoroquinolones, patients with renal failure, or history of tendon disorders 1
Discontinue immediately if tendon rupture occurs; consider discontinuation if joint pain, swelling, or inflammation develops 2, 1.
Liver Enzyme Monitoring:
While not specifically mandated, elevated liver enzymes are a recognized adverse effect 2. Periodic monitoring is reasonable, particularly in the first months of therapy.
Contraindications
The only absolute contraindication is a history of serious hypersensitivity reaction to bempedoic acid or any excipients, including angioedema 1.
Important Precautions:
- Avoid in patients with history of tendon disorders or tendon rupture 1
- Discontinue when pregnancy is recognized unless benefits clearly outweigh fetal risks 2
- Breastfeeding is not recommended 1
Cardiovascular Outcomes Evidence
Bempedoic acid reduces myocardial infarction risk (RR 0.76,95% CI 0.65-0.89) based on the CLEAR Outcomes trial 4. This represents a small but clinically meaningful reduction of 15 fewer MIs per 1000 patients treated.
However, the drug does not significantly reduce:
- All-cause mortality (RR 1.19,95% CI 0.73-1.93) 4
- CV-related mortality (RR 1.05,95% CI 0.89-1.24) 4
- Stroke (RR 0.87,95% CI 0.69-1.08) 4
The primary benefit is in reducing myocardial infarction and coronary revascularization events in statin-intolerant patients 6.
Common Adverse Effects
The most frequent adverse effects include 2:
- Upper respiratory tract infection
- Muscle spasms (despite hepatic-specific activation)
- Hyperuricemia
- Back pain
- Abdominal pain or discomfort
- Bronchitis
- Pain in extremity
- Anemia
- Elevated liver enzymes
Critically, bempedoic acid does not increase muscle-related symptoms compared to placebo, even in statin-intolerant patients 7, 3. Myalgia occurred in only 4.7% of bempedoic acid patients versus 7.2% of placebo patients in the CLEAR Serenity trial 3.
Practical Considerations
Cost and prior authorization requirements may limit access 2. Patient assistance programs and discount copay cards are available for eligible patients 2.
The fixed-dose combination with ezetimibe may improve adherence in patients requiring multiple lipid-lowering agents 2. This combination provides robust LDL-C lowering (38% reduction when added to statins) with once-daily dosing 2.
Greatest LDL-C reductions occur in patients with continuous use and those without background statin therapy 5, emphasizing the importance of medication adherence and the drug's utility as monotherapy in truly statin-intolerant patients.